Latest Health News

Pro Medicus Limited has delivered a record interim profit of $51.7 million, boosted by major North American contract wins and strong margin expansion.

Pro Medicus Limited delivered a robust half-year performance ending December 2024, with after-tax profits soaring 42.7% to $51.74 million and revenues climbing 31.1% to $97.2 million, driven by significant contract wins in North America and sustained growth in Australia.

Viva Leisure has delivered a robust first half of FY25, reporting a 25.2% increase in revenue and a 26.2% rise in EBITDA, driven by strong execution across its health clubs, franchise network, and technology divisions.

Viva Leisure has delivered record revenue and profitability in the first half of FY2025, driven by robust membership growth and technology integration, reaffirming its strategic focus on operational efficiency and cash flow generation.

Downer EDI Limited has reported a strong financial turnaround in the first half of FY25, with significant earnings growth and improved cash flow despite a revenue decline influenced by divestments and softer market conditions.

Micro-X Ltd has launched the retail component of its $6 million capital raising, offering eligible shareholders the chance to buy new shares at 7 cents each, aiming to raise $2.7 million by late February 2025.

Orora Limited has announced a 5-cent per share ordinary dividend for the six months ending December 2024, payable in April 2025. The dividend is unfranked and offers shareholders a Dividend Reinvestment Plan option.

Treasury Wine Estates reports a robust first half of 2025, driven by luxury portfolio growth and DAOU integration, while premium segments face headwinds.

HomeCo Daily Needs REIT reported solid 1H FY25 results with stable FFO and DPU per unit, underpinned by a $4.8 billion portfolio and a robust development pipeline targeting strong returns.

Nuchev Limited has appointed Nathan Cheong as its new CEO, with current CEO Mick Myers transitioning to COO and CFO roles, signaling a strategic leadership evolution.

Artrya has secured a pivotal three-year commercial contract with Sonic Healthcare Australia to deploy its AI-driven Salix Coronary Anatomy platform across over 125 radiology centres, marking a significant step in commercialising its coronary artery disease diagnostic technology.

Island Pharmaceuticals has successfully completed patient dosing in the Phase 2b therapeutic arm of its PROTECT clinical trial for ISLA-101, targeting dengue fever treatment. High-level results are expected within two months, potentially advancing a significant antiviral candidate.